XBIState Street SPDR S&P Biotech ETF

Grow my money20y track recordRanked #155 of 3,051 in this goal

Tracks the total return performance of the S&P Biotechnology Select Industry Index.

By State Street Investment Management · Launched 2006

Annual Cost

0.35%

#1,699 of 6,035 · low cost

Fund Size

$11.4B

#263 of 6,035 · large

Return (1Y)

+64.4%

Track Record

20 years

#266 of 6,035 · established

Performance

Total-return NAV · USD

Growth of $10,000

$14,435+44.4%

Total-return NAV, USD. Net of fund fees, before tax.

What's inside

How Beacon categorizes this fund

Asset class

Equity

Region

North america

Cap

Multi cap

Strategy

Index tracking

Sector

Health care

Focus

Biotech & Genomics

Index tracked

S&P Biotechnology Select Industry Index

Holdings

By weight

Concentration

Top 10 holdings = 20.4% of funddiversified

State Street Global Advisors

8.0%

Apellis Pharmaceuticals Inc

1.8%

Alkermes PLC

1.5%

Madrigal Pharmaceuticals Inc

1.4%

TG Therapeutics Inc

1.3%

Insmed Inc

1.3%

Scholar Rock Holding Corp

1.3%

Apogee Therapeutics Inc

1.3%

Protagonist Therapeutics Inc

1.2%

Summit Therapeutics Inc

1.2%

Asset allocation

Stocks

100.0%

Cash

0.0%

By sector

Healthcare

99.3%

Financial Services

0.7%

Risk profile

Last 12 months · Sharpe & Sortino need 3+ years

Volatility (1Y)

27.9%High

Year-on-year price swings

Max drawdown

-63.9%Severe

Worst peak-to-trough loss

Sharpe (3Y)

0.81Decent risk-adjusted returns

Sortino (3Y)

1.19Good downside protection

Listing

Exchange: NYSE Arca

Full fund details

Objective: Tracks the total return performance of the S&P Biotechnology Select Industry Index.
Strategy: Invests primarily in U.S. biotechnology companies with float-adjusted market capitalizations of at least $500 million, using a sampling strategy to track the S&P Biotechnology Select Industry Index. The Fund may also invest in cash and cash equivalents for management purposes.
Inception date: January 31, 2006
Fund family: State Street Investment Management